Nanjing LeadsBiolabs Biotechnology Co , Ltd announced that its self-developed, global intellectual property TNFR2 monoclonal antibody LBL-019 clinical trial application has been approved by the US FDA for clinical trials
Nanjing Zenshine Pharma announced that First patient received ZX-4081 treatment in the phase 1 trial!
On January 4, 2022, Zenshine Pharma announced that ZX-4081 was dosed to the first patient in the US
Medomics’ Covid antigen kit passed the TGA (Australian Medicines and Medical Device Administration) registration and was approved for sale
Biosion authorized OBI Pharma BSI04702 (anti-TROP2 monoclonal antibody) global development and commercialization rights!
Biosion announced the signing of an exclusive license agreement with Taiwan OBI Pharma Co , Ltd